UPDATE: RedHill Biopharma CEO Tells Benzinga FDA Has Told Co. Strong Enough Results In Its BEKINDA Phase 3 Trial Will Warrant NDA Application Without Further Study, Says FDA Hasn't Communicated Exact Significance That Must Be Met